izokibep + prednisone

**Izokibep + prednisone** is a combination therapy of two drugs: - **Izokibep** is a small, biological ligand trap designed to selectively inhibit interleukin 17A (IL-17A) by using engineered Affibody domains that bind with high affinity to IL-17A, blocking its signaling via the IL-17 receptor. This molecule consists of two IL-17A-specific Affibody domains and one albumin-binding domain, which extends plasma half-life. Izokibep targets autoimmune diseases where IL-17A plays a pivotal pathogenic role, such as psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis. It has demonstrated superior potency over anti-IL-17A monoclonal antibodies in vitro and in vivo[1]. - **Prednisone** is a synthetic glucocorticoid corticosteroid that acts as a broad-spectrum immunosuppressant and anti-inflammatory agent by modulating gene transcription and inhibiting multiple inflammatory cytokines. This combination would leverage targeted cytokine inhibition (izokibep) with systemic immunosuppression (prednisone), though no specifically named or branded combination product is currently marketed; the combination could be used in investigational or off-label contexts in autoimmune or inflammatory diseases.